{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T01:56:05Z","timestamp":1780624565399,"version":"3.54.1"},"reference-count":24,"publisher":"American Diabetes Association","issue":"8","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2001,8,1]]},"abstract":"<jats:p>OBJECTIVE\u2014To investigate cardiovascular drug use and hospitalizations attributable to type 2 diabetes from 1 year before until 6 years after the start of oral antidiabetic therapy.<\/jats:p>\n               <jats:p>RESEARCH DESIGN AND METHODS\u2014In this cohort study, 2,584 patients with type 2 diabetes were selected from the PHARMO Record Linkage System, comprising pharmacy records and hospitalizations for all 320,000 residents of six Dutch cities. Patients with type 2 diabetes were identified as incident oral antidiabetic drug users between 1992 and 1997. Nondiabetic subjects were 1:1\u2013matched for age, sex, pharmacy, and index date and received no insulin, oral antidiabetic drugs, or glucose-testing supplies.<\/jats:p>\n               <jats:p>RESULTS\u2014Patients with type 2 diabetes were more likely to use cardiovascular drugs (RR 1.28 [95% CI 1.23\u20131.34]) and to be hospitalized because of cardiovascular diseases (1.54 [1.33\u20131.78]) after the start of oral antidiabetic therapy than nondiabetic subjects. Differences between patients with type 2 diabetes and nondiabetic subjects lessened from 1 year before until 6 years after the start of oral antidiabetic therapy, reflected by decreasing attributable risks for diuretics, \u03b2-blockers, calcium channel blockers, and cardiac and antithrombotic drugs. The difference in use of angiotensin-converting enzyme inhibitors and lipid-lowering drugs increased. Cardiovascular hospitalizations attributable to type 2 diabetes were \u223c50% in the years close to the start of oral antidiabetic treatment and decreased to \u223c33% in the following years.<\/jats:p>\n               <jats:p>CONCLUSIONS\u2014Although cardiovascular drug use and hospitalizations remained increased in patients with type 2 diabetes after the start of oral antidiabetic therapy, cardiovascular drug use attributable to type 2 diabetes decreased after the start of oral antidiabetic therapy, especially \u03b2-blockers, whereas cardiovascular hospitalizations first decreased and then stabilized.<\/jats:p>","DOI":"10.2337\/diacare.24.8.1428","type":"journal-article","created":{"date-parts":[[2007,3,5]],"date-time":"2007-03-05T22:51:27Z","timestamp":1173135087000},"page":"1428-1432","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":11,"title":["Cardiovascular Drug Use and Hospitalizations Attributable to Type 2 Diabetes"],"prefix":"10.2337","volume":"24","author":[{"given":"Joe\u0308lle A.","family":"Erkens","sequence":"first","affiliation":[{"name":"Department of Pharmacoepidemiology and Pharmacotherapy and the"},{"name":"Julius Center for Patient Oriented Research, Utrecht University, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf H.","family":"Klungel","sequence":"additional","affiliation":[{"name":"Department of Pharmacoepidemiology and Pharmacotherapy and the"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald P.","family":"Stolk","sequence":"additional","affiliation":[{"name":"Julius Center for Patient Oriented Research, Utrecht University, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose\u0301 A.","family":"Spoelstra","sequence":"additional","affiliation":[{"name":"Department of Pharmacoepidemiology and Pharmacotherapy and the"},{"name":"Julius Center for Patient Oriented Research, Utrecht University, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diederick E.","family":"Grobbee","sequence":"additional","affiliation":[{"name":"Julius Center for Patient Oriented Research, Utrecht University, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert G.M.","family":"Leufkens","sequence":"additional","affiliation":[{"name":"Department of Pharmacoepidemiology and Pharmacotherapy and the"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","reference":[{"key":"2022031214392256000_R1","doi-asserted-by":"crossref","unstructured":"Wandell PE, Brorsson B, Aberg H: Drug use in patients with diabetes. Diabetes Care\u200819: 992\u2013994, 1996","DOI":"10.2337\/diacare.19.9.992"},{"key":"2022031214392256000_R2","doi-asserted-by":"crossref","unstructured":"Rendell M, Lassek WD, Ross DA, Smith C, Kernek S, Williams J, Brown M, Willingmyre L, Yamamoto L: A pharmaceutical profile of diabetic patients. J Chronic Dis\u200836:193\u2013202, 1983","DOI":"10.1016\/0021-9681(83)90093-0"},{"key":"2022031214392256000_R3","doi-asserted-by":"crossref","unstructured":"Isacson D, Stalhammar J: Prescription drug use among diabetics: a population study. J Chronic Dis\u200840:651\u2013660, 1987","DOI":"10.1016\/0021-9681(87)90101-9"},{"key":"2022031214392256000_R4","doi-asserted-by":"crossref","unstructured":"Glauber HS, Brown JB: Use of health maintenance organization data bases to study pharmacy resource usage in diabetes mellitus. Diabetes Care\u200815:870\u2013876, 1992","DOI":"10.2337\/diacare.15.7.870"},{"key":"2022031214392256000_R5","doi-asserted-by":"crossref","unstructured":"Evans JM, MacDonald TM, Leese GP, Ruta DA, Morris AD: Impact of type 1 and type 2 diabetes on patterns and costs of drug prescribing: a population-based study. Diabetes Care\u200823:770\u2013774, 2000","DOI":"10.2337\/diacare.23.6.770"},{"key":"2022031214392256000_R6","doi-asserted-by":"crossref","unstructured":"Gram J, Damsgaard EM: Drug consumption in elderly diabetics. Diabetes Res Clin Pract\u20087:293\u2013298, 1989","DOI":"10.1016\/0168-8227(89)90018-1"},{"key":"2022031214392256000_R7","doi-asserted-by":"crossref","unstructured":"Ramsey SD, Newton K, Blough D, McCulloch DK, Sandhu N, Wagner EH: Patient-level estimates of the cost of complications in diabetes in a managed-care population. Pharmacoeconomics\u200816:285\u2013295, 1999","DOI":"10.2165\/00019053-199916030-00005"},{"key":"2022031214392256000_R8","doi-asserted-by":"crossref","unstructured":"Brown JB, Pedula KL, Bakst AW: The progressive cost of complications in type 2 diabetes mellitus. Arch Intern Med\u2008159:1873\u20131880, 1999","DOI":"10.1001\/archinte.159.16.1873"},{"key":"2022031214392256000_R9","doi-asserted-by":"crossref","unstructured":"Brown JB, Nichols GA, Glauber HS, Bakst AW: Type 2 diabetes: incremental medical care costs during the first 8 years after diagnosis. Diabetes Care\u200822:1116\u20131124, 1999","DOI":"10.2337\/diacare.22.7.1116"},{"key":"2022031214392256000_R10","doi-asserted-by":"crossref","unstructured":"Herings RM, Bakker A, Stricker BH, Nap G: Pharmaco-morbidity linkage: a feasibility study comparing morbidity in two pharmacy based exposure cohorts. J Epidemiol Community Health\u200846:136\u2013140, 1992","DOI":"10.1136\/jech.46.2.136"},{"key":"2022031214392256000_R11","unstructured":"Rothman KJ, Greenland S: Modern Epidemiology. Philadelphia, PA, Lippincott-Raven, 1998"},{"key":"2022031214392256000_R12","doi-asserted-by":"crossref","unstructured":"Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care\u200820:614\u2013620, 1997","DOI":"10.2337\/diacare.20.4.614"},{"key":"2022031214392256000_R13","doi-asserted-by":"crossref","unstructured":"U.K. Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ\u2008317:703\u2013713, 1998","DOI":"10.1136\/bmj.317.7160.703"},{"key":"2022031214392256000_R14","doi-asserted-by":"crossref","unstructured":"Zuanetti G, Latini R, Maggioni AP, Franzosi M, Santoro L, Tognoni G: Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. Circulation\u200896:4239\u20134245, 1997","DOI":"10.1161\/01.CIR.96.12.4239"},{"key":"2022031214392256000_R15","doi-asserted-by":"crossref","unstructured":"U.K. Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ\u2008317:713\u2013720, 1998","DOI":"10.1136\/bmj.317.7160.713"},{"key":"2022031214392256000_R16","doi-asserted-by":"crossref","unstructured":"Epstein M, Sowers JR: Diabetes mellitus and hypertension. Hypertension\u200819:403\u2013418, 1992","DOI":"10.1161\/01.HYP.19.5.403"},{"key":"2022031214392256000_R17","doi-asserted-by":"crossref","unstructured":"Kjekshus J, Gilpin E, Cali G, Blackey AR, Henning H, Ross J Jr: Diabetic patients and beta-blockers after acute myocardial infarction. Eur Heart  J\u200811:43\u201350, 1990","DOI":"10.1093\/oxfordjournals.eurheartj.a059591"},{"key":"2022031214392256000_R18","doi-asserted-by":"crossref","unstructured":"O\u2019Byrne S, Feely J: Effects of drugs on glucose tolerance in non-insulin-dependent diabetics: part I. Drugs\u200840:6\u201318, 1990","DOI":"10.2165\/00003495-199040010-00002"},{"key":"2022031214392256000_R19","unstructured":"Yudkin JS, Blauth C, Drury P, Fuller J, Henley J, Lancaster T, Lankester J, Lean M, Pentecost B, Press V, Rothman D: Prevention and management of cardiovascular disease in patients with diabetes mellitus: an evidence base. Diabet Med\u200813:S101\u2013S121, 1996"},{"key":"2022031214392256000_R20","doi-asserted-by":"crossref","unstructured":"Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL: Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus: Atherosclerosis Risk in Communities Study. N Engl J Med\u2008342:905\u2013912, 2000","DOI":"10.1056\/NEJM200003303421301"},{"key":"2022031214392256000_R21","doi-asserted-by":"crossref","unstructured":"Fava S, Azzopardi J, Agius-Muscat H: Outcome of unstable angina in patients with diabetes mellitus. Diabet Med\u200814:209\u2013213, 1997","DOI":"10.1002\/(SICI)1096-9136(199703)14:3<209::AID-DIA324>3.0.CO;2-B"},{"key":"2022031214392256000_R22","doi-asserted-by":"crossref","unstructured":"Grootenhuis PA, Snoek FJ, Heine RJ, Bouter LM: Development of a type 2 diabetes symptom checklist: a measure of symptom severity. Diabet Med\u200811:253\u2013261, 1994","DOI":"10.1111\/j.1464-5491.1994.tb00268.x"},{"key":"2022031214392256000_R23","doi-asserted-by":"crossref","unstructured":"Harris MI: Undiagnosed NIDDM: clinical and public health issues. Diabetes Care\u200816:642\u2013652, 1993","DOI":"10.2337\/diacare.16.4.642"},{"key":"2022031214392256000_R24","doi-asserted-by":"crossref","unstructured":"Mooy JM, Grootenhuis PA, de Vries H, Valkenburg HA, Bouter LM, Kostense PJ, Heine RJ: Prevalence and determinants of glucose intolerance in a Dutch caucasian population: the Hoorn Study. Diabetes Care\u200818:1270\u20131273, 1995","DOI":"10.2337\/diacare.18.9.1270"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/24\/8\/1428\/643777\/1428.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/24\/8\/1428\/643777\/1428.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T14:39:31Z","timestamp":1647095971000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/24\/8\/1428\/21567\/Cardiovascular-Drug-Use-and-Hospitalizations"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,8,1]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2001,8,1]]}},"URL":"https:\/\/doi.org\/10.2337\/diacare.24.8.1428","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,8,1]]}}}